ASCO 2024: Telehealth can significantly reduce greenhouse gas emissions associated with cancer care, study finds
Telemedicine visits for cancer care may not only be more convenient and easier to schedule…
Browsing: ASCO
ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that…
ASCO 2024: Spanish-language content for lung cancer patients helps break down barriers to care
Estelamari Rodriguez, M.D., M.P.H., is the recipient of the Patient Educator of the Year award…
ASCO 2024: Research group completes first trial of Black patients with early-stage breast cancer
Black patients with early-stage breast cancer who were treated with docetaxel chemotherapy every 3 weeks…
ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC
For patients with previously untreated, advanced non-small cell lung cancer (NSCLC) with an anaplastic lymphoma…
ASCO 2024: Prostate cancer spit test better for men with high genetic risk than standard blood test
A spit test, where a sample can be collected at home, is more accurate at…
ASCO 2024: Novel therapy combination more effective at treating Hodgkin lymphoma than established treatment
A new study showed that BrECADD, a novel therapy combination, cured classic Hodgkin lymphoma more…
ASCO 2024: Shorter durations of venetoclax yields similar response rates in AML
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was…
ASCO 2024: Adding belantamab mafodotin to multiple myeloma treatment combinations slows disease progression or death
According to a new study, adding belantamab mafodotin to pomalidomide and dexamethasone for the treatment…
ASCO 2024: Risk reduction from HPV vaccination goes beyond cervical cancer
Results from a new study suggest that the human papillomavirus (HPV) vaccine is effective in…